




Instance: composition-en-188ccb87c0d4f4c736200f4cfc1c3e01
InstanceOf: CompositionUvEpi
Title: "Composition for proquad Package Leaflet"
Description:  "Composition for proquad Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp0ef0c8cd9fea74a67baf8cc292ab700b)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - proquad"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What ProQuad is and what it is used for</li>
<li>What you need to know before you receive  ProQuad</li>
<li>How to use ProQuad</li>
<li>Possible side effects</li>
<li>How to store ProQuad</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What proquad is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What proquad is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>ProQuad is a vaccine containing measles, mumps, rubella, and chickenpox (varicella) viruses that
have been weakened. When a person is given the vaccine, the immune system (the body s natural
defences) will make antibodies against the measles, mumps, rubella, and varicella viruses. The
antibodies help protect against diseases caused by these viruses.
ProQuad is given to help protect your child against measles, mumps, rubella, and chickenpox
(varicella). The vaccine may be administered to persons from 12 months of age.
ProQuad may also be administered to infants from 9 months of age under special circumstances (to
conform with national vaccination schedules, outbreak situations, or travel to a region with high
prevalence of measles).
Although ProQuad contains live viruses, they are too weak to cause measles, mumps, rubella, or
chickenpox (varicella) in healthy people.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take proquad"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take proquad"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use ProQuad</p>
<p>If the person to be vaccinated is allergic to any varicella vaccine or measles, mumps, or rubella
vaccine or to any of the ingredients of this vaccine (listed in section 6) including neomycin.</p>
<p>If the person to be vaccinated has a blood disorder or any type of cancer that affects the
immune system.</p>
<p>If the person to be vaccinated is receiving treatment or taking medications that may weaken the
immune system (except low-dose corticosteroid therapy for asthma or replacement therapy).</p>
<p>If the person to be vaccinated has a weakened immune system because of a disease (including
AIDS).</p>
<p>If the person to be vaccinated has a family history of congenital or hereditary
immunodeficiency, unless the immune competence of this person is demonstrated.</p>
<p>If the person to be vaccinated has active untreated tuberculosis.</p>
<p>If the person to be vaccinated has any illness with fever higher than 38.5 C; however, low-
grade fever itself is not a reason to delay vaccination.</p>
<p>If the person to be vaccinated is pregnant (in addition, pregnancy should be avoided for 1
month after vaccination, see Pregnancy and breast-feeding).
Warnings and precautions
If the person to be vaccinated has experienced any of the following, talk to the doctor or pharmacist
before ProQuad is given:</p>
<p>An allergic reaction to eggs or anything that contained egg.</p>
<p>A history or family history of allergies or of convulsions (fits).</p>
<p>A side effect after vaccination with measles, mumps, and/or rubella-containing vaccines that
involved easy bruising or bleeding for longer than usual.</p>
<p>An infection with Human Immunodeficiency Virus (HIV) without showing symptoms of HIV
disease. However, vaccination may be less effective than for uninfected persons (see Do not
use ProQuad).
If you have a blood clotting disorder or low levels of platelets in your blood, the injection will be
given under the skin.
In rare circumstances, it is possible to catch chickenpox, including severe chickenpox, from a person
who has been vaccinated with ProQuad. This may occur in persons who have not previously been
vaccinated against chickenpox or had chickenpox, as well as persons who fall into one of the
following categories:</p>
<p>Individuals with a lowered resistance to diseases.</p>
<p>Pregnant women who have either not had chickenpox or have not been vaccinated against
chickenpox.</p>
<p>Newborn infants of mothers who have either not had chickenpox or have not been vaccinated
against chickenpox.
Whenever possible, individuals who have been vaccinated with ProQuad should attempt to avoid
close contact, for up to 6 weeks following the vaccination, with anyone who falls into one of the
categories above. Tell your doctor if there is anyone who falls into one of the categories above and is
expected to be in close contact with the person being vaccinated.
As with other vaccines, ProQuad may not completely protect all persons who are vaccinated. Also, if
the person to be vaccinated has already been exposed to the measles, mumps, rubella, or varicella
virus but is not yet ill, ProQuad may not be able to prevent the illness from appearing.
Other medicines and ProQuad
Tell your doctor or pharmacist if the person to be vaccinated is taking or has recently taken any other
medicines (or other vaccines).
ProQuad can be given at the same time as other childhood vaccines such as Prevenar, and/or hepatitis
A vaccine, or with vaccines containing diphtheria, tetanus, acellular pertussis, Haemophilus
influenzae type b, inactivated poliomyelitis, or hepatitis B. A different place for the injection will be
used for each vaccine.
The doctor may delay vaccination for at least 3 months following blood or plasma transfusions, or
administration of immune globulin (IG), or varicella-zoster immune globulin (VZIG). After
vaccination with ProQuad, IG or VZIG should not be given for 1 month, unless your doctor tells you
otherwise. 
If a tuberculin test is to be performed, it should be done either any time before, simultaneously with,
or 4 to 6 weeks after vaccination with ProQuad.</p>
<p>Tell the doctor if the person to be vaccinated has recently received a vaccine or if one is scheduled to
be given in the near future. The doctor will determine when ProQuad may be given. 
The use of salicylates (for example, acetylsalicylic acid, a substance present in many medicines used
to relieve pain and lower fever) should be avoided for 6 weeks following vaccination with ProQuad.
Pregnancy and breast-feeding
ProQuad should not be given to pregnant women. Women of child-bearing age should take the
necessary precautions to avoid pregnancy for 1 month following vaccination.
Persons who are breast-feeding or who intend to breast-feed should tell the doctor. The doctor will
decide if ProQuad should be given.
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask
your doctor or pharmacist for advice before taking this vaccine.
ProQuad contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially  sodium-
free .
ProQuad contains potassium
This medicine contains less than 1 mmol potassium (39 mg) per dose, that is to say essentially
 potassium-free .
ProQuad contains sorbitol
This medicine contains 16 mg sorbitol per dose. The additive effect of concomitantly administered
products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken
into account.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take proquad"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take proquad"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>ProQuad should be injected into the muscle or under the skin either in the area of the outer thigh or of
the upper arm.
Usually for injections into the muscle the thigh area is preferred in young children, whereas for older
individuals the upper arm area is the preferred injection site.
If the person to be vaccinated has a blood clotting disorder or low levels of platelets, the vaccine
should be given under the skin because bleeding may occur following administration into the muscle.
ProQuad is not to be injected directly into any blood vessel. 
ProQuad is given by injection as follows: </p>
<p>Infants between 9 and 12 months of age:</p>
<p>ProQuad may be administered from 9 months of age. To ensure optimal protection against
chickenpox and measles, two doses of ProQuad should be given at least three months apart. </p>
<p>Individuals 12 months of age and older:</p>
<p>To ensure optimal protection against chickenpox, two doses of ProQuad should be given at
least one month apart.
The appropriate time and number of injections will be determined by your doctor in accordance with
official recommendations.</p>
<p>Reconstitution instructions intended for medical and healthcare professionals are included at
the end of the leaflet
If you forget to take ProQuad
Your doctor will decide when to give the missed dose.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all vaccines and medicines, this vaccine can cause side effects, although not everybody gets
them.
Allergic reactions (hives) may occur. Some of these reactions may be serious and may include
difficulty in breathing or swallowing. If the vaccinated person has an allergic reaction, call your
doctor right away.
Other side effects have been reported following administration of ProQuad and some of these were
serious. These included:</p>
<p>Uncommon (may affect up to 1 in 100 people): seizures with a fever. </p>
<p>Rare (may affect up to 1 in 1,000 people): unsteadiness with walking.
The following other side effects reported with the use of ProQuad were:</p>
<p>Very common (may affect more than 1 in 10 people): injection site complaints including
pain/tenderness/soreness, redness, fever (38.9 C or higher);</p>
<p>Common (may affect up to 1 in 10 people): injection site complaints including swelling or
bruising; irritability; rash (including measles-like rash, varicella-like rash, and injection-site
rash); upper respiratory infection; vomiting and diarrhoea.
Other side effects have been reported with the use of at least one of the following: ProQuad, previous
formulations of monovalent and of the combined measles, mumps, and rubella vaccines manufactured
by Merck &amp; Co., Inc., or Varicella Vaccine live (Oka/Merck). These adverse events include: </p>
<p>Uncommon (may affect up to 1 in 100 people): cough.</p>
<p>Rare (may affect up to 1 in 1,000 people): skin infection; chickenpox (varicella).</p>
<p>Not known (frequency cannot be estimated from the available data): unusual bleeding or
bruising under the skin, swelling of the testicles; tingling of the skin, herpes zoster (shingles);
inflammation of the brain (encephalitis); inflammation of the coverings of the brain and spinal
cord not caused by bacterial infection (aseptic meningitis), severe skin disorders; stroke;
seizures without a fever; joint pain and/or swelling (which could be transient or chronic); and
inflammation of the lung (pneumonia/pneumonitis).
The doctor has a more complete list of side effects for ProQuad and for the vaccine components for
ProQuad (the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. and Varicella
Vaccine live (Oka/Merck)).
Reporting of side effects
If the vaccinated person gets any side effects, talk to your doctor or pharmacist. This includes any
possible side effects not listed in this leaflet. You can also report side effects directly via the national
reporting system listed in Appendix V. By reporting side effects you can help provide more
information on the safety of this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store proquad"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store proquad"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this vaccine out of the sight and reach of children.</p>
<p>Do not use this vaccine after the expiry date which is stated on the outer carton after EXP. The expiry
date refers to the last day of that month.
Store and transport refrigerated (2 C-8 C).
Do not freeze.
Keep the vial in the outer carton in order to protect from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help protect the environment.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What ProQuad contains
After reconstitution, one dose (0.5 mL) contains:
The active substances are:
Measles virus1 Enders  Edmonston strain (live, attenuated) ........ not less than 3.00 log10 TCID50<em> Mumps virus1 Jeryl Lynn <br />
 (Level B) strain (live, attenuated) ... not less than 4.30 log10 TCID50</em> Rubella virus2 Wistar RA 27/3 strain (live, attenuated)............... not less than 3.00 log10 TCID50<em> Varicella virus3 Oka/Merck strain (live, attenuated) ................... not less than 3.99 log10 PFU</em><em> </em>50% tissue culture infectious dose
** plaque-forming units
(1) Produced in chick embryo cells. 
(2) Produced in human diploid lung (WI-38) fibroblasts. 
(3) Produced in human diploid cells (MRC-5). 
The other ingredients are:
Powder
Sucrose, hydrolysed gelatin, urea, sodium chloride, sorbitol (E 420), monosodium glutamate, sodium
phosphate, sodium bicarbonate, potassium phosphate, potassium chloride, medium 199 with Hanks 
Salts, MEM, neomycin, phenol red, hydrochloric acid and sodium hydroxide.
Solvent
Water for injections.
What ProQuad looks like and contents of the pack
The vaccine is a powder for suspension for injection contained in a single-dose vial, which should be
mixed with solvent provided with the vial of powder.
The powder is a white to pale yellow compact crystalline cake and the solvent is a clear colourless
liquid.
ProQuad is available in pack of 1 and pack of 10. Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder: Merck Sharp &amp; Dohme B.V., Waarderweg 39, 2031 BN Haarlem,
The Netherlands
Manufacturer Responsible for Batch Release: Merck Sharp and Dohme, B.V., Waarderweg, 39, 2BN Haarlem, The Netherlands</p>
<p>For any information about this medicinal product, please contact the local representative of the
Marketing Authorisation Holder.
Belgi /Belgique/Belgien
MSD Belgium
T l/Tel: +32(0)27766dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel.: +370.5.2780.msd_lietuva@merck.com</p>
<pre><code>       ,
</code></pre>
<p>.: + 359 2 819 3info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium
T l/Tel: +32(0)27766dpoc_belux@merck.com
 esk  republika
Merck Sharp &amp; Dohme s.r.o. 
Tel.: +420 233 010 dpoc_czechslovak@merck.com
Magyarorsz g
MSD Pharma Hungary Kft.
Tel.: + 36.1.888.5hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf: + 45 4482 4dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited.
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999(+31 23 5153153)
medicalinfo.nl@merck.com
Eesti
Merck Sharp &amp; Dohme O 
Tel.: +372 6144 msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 msdnorge@msd.no</p>
<p>MSD  . . . . .
 : +30 210 98 97 dpoc_greece@merck.com
 sterreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 dpoc_austria@merck.com
Espa a
Merck Sharp &amp; Dohme de Espa a, S.A.
Tel: +34 91 321 06 msd_info@merck.com
Polska
MSD Polska Sp. z o.o.
Tel.: +48.22.549.51.msdpolska@merck.com
France
MSD France
Tel:+ 33 (0)1 80 46 40 Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465inform_pt@merck.com
Hrvatska
Merck Sharp &amp; Dohme d.o.o.
Tel: +385 1 66 11 croatia_info@merck.com
Rom nia
Merck Sharp &amp; Dohme Romania S.R.L
Tel: + 4021 529 29 msdromania@merck.com</p>
<p>Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfo_ireland@merck.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila d.o.o.
Tel: +386.1.520.4msd.slovenia@merck.com
 sland
Vistor hf.
S mi: + 354 535 7Slovensk  republika
Merck Sharp &amp; Dohme, s. r.* Tel: +421 2 58282dpoc_czechslovak@merck.com
Italia
MSD Italia S.r.l. 
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 info@msd.fi</p>
<p>Merck Sharp &amp; Dohme Cyprus Limited
 : 800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700medicinskinfo@merck.com
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: +371.67364.msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfoNI@msd.com
This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website:
http://www.ema.europa.eu.</p>
<hr />
<p>The following information is intended for healthcare professionals only:
Before mixing with the solvent, the powder vaccine is a white to pale yellow compact crystalline
cake. The solvent is a clear colourless liquid. When completely reconstituted, the vaccine is a clear
pale yellow to light pink liquid.
To reconstitute the vaccine, use only the solvent supplied, because it is free of preservatives or other
antiviral substances, which might inactivate the vaccine.
It is important to use a separate sterile syringe and needle for each individual to prevent transmission
of infectious agents from one individual to another.
One needle should be used for reconstitution and a separate, new needle for injection.
ProQuad must not be mixed in a syringe with other vaccines.
Reconstitution instructions</p>
<p>Withdraw the entire content of the solvent vial into a syringe. Inject the entire content of the syringe
into the vial containing the powder. Gently agitate to dissolve completely.
The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or
abnormal physical appearance prior to administration. In the event of either being observed, discard
the vaccine.
It is recommended that the vaccine be administered immediately after reconstitution to
minimize loss of potency. Discard if reconstituted vaccine is not used within 30 minutes.
Do not freeze the reconstituted vaccine.
Withdraw the entire content of the reconstituted vaccine from the vial into a syringe, change the
needle, and inject the entire volume by subcutaneous or intramuscular route.
Any unused product or waste material should be disposed of in accordance with local requirements.
See also section 3 How to use ProQuad.</p>
<p>Package leaflet: Information for the User
ProQuad
Powder and solvent for suspension for injection in a pre-filled syringe
Measles, mumps, rubella and varicella vaccine (live)
Read all of this leaflet carefully before you or your child is vaccinated because it contains
important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or your pharmacist.
- This vaccine has been prescribed for you or your child only. Do not pass it on to others.
- If you get any of the side effects talk to your doctor of pharmacist. This includes any possible
side effects not listed in this leaflet. See section 4.</p>         </div>"""      



Instance: composition-da-188ccb87c0d4f4c736200f4cfc1c3e01
InstanceOf: CompositionUvEpi
Title: "Composition for proquad Package Leaflet"
Description:  "Composition for proquad Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp0ef0c8cd9fea74a67baf8cc292ab700b)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - proquad"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse
2. Det skal du vide, før du eller dit barn får ProQuad
3. Sådan får du ProQuad
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What proquad is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What proquad is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>ProQuad er en vaccine, der indeholder svækket virus af mæslinger, fåresyge, røde hunde og
skoldkopper (varicella). Når en person vaccineres med ProQuad, danner immunsystemet (kroppens
naturlige forsvar) antistoffer mod mæslinge-, fåresyge-, røde hunde- og skoldkoppevirus.
Antistofferne er med til at beskytte mod sygdomme, der skyldes disse virus.
ProQuad gives for at beskytte dit barn mod mæslinger, fåresyge, røde hunde og skoldkopper
(varicella). Vaccinen kan gives til personer, fra de er 12 måneder.
ProQuad kan også gives til spædbørn fra 9-måneders alderen under særlige omstændigheder (i
overensstemmelse med nationale vaccinationsprogrammer, i forbindelse med sygdomsudbrud eller
ved rejse til et område med høj forekomst af mæslinger).
Selv om ProQuad indeholder levende virus, er disse for svage til at udløse mæslinger, fåresyge, røde
hunde eller skoldkopper (varicella) hos raske mennesker.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take proquad"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take proquad"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du / dit barn må ikke få ProQuad
 
Hvis personen, der skal vaccineres, er allergisk over for en vaccine med skoldkoppevirus
eller med mæslinge-, fåresyge- eller røde hundevirus eller over for et eller flere af
hjælpestofferne i denne vaccine (angivet i afsnit 6), inklusive neomycin. 
 
Hvis personen, der skal vaccineres, har en blodsygdom eller en kræftsygdom, der påvirker
immunsystemet.
 
Hvis personen, der skal vaccineres, er i behandling eller får medicin, der kan svække
immunsystemet (undtagen lave doser af kortikosteroider mod astma eller som
substitutionsterapi).
 
Hvis personen, der skal vaccineres, har et svækket immunsystem på grund af sygdom
(inklusive aids).</p>
<p>40
 
Hvis der er en medfødt eller arvelig immundefekt i familien, medmindre der er påvist, at
den person, der skal vaccineres, ikke har nedsat immunforsvar.
 
Hvis personen, der skal vaccineres, har aktiv, ubehandlet tuberkulose.
 
Hvis personen, der skal vaccineres, er syg og har over 38,5 °C i feber. Lav feber alene er
ikke grund nok til at udsætte vaccinationen.
 
Hvis personen, der skal vaccineres, er gravid (graviditet bør desuden undgås i 1 måned
efter vaccinationen, se Graviditet og amning).
Advarsler og forsigtighedsregler
Hvis personen, der skal vaccineres, har været udsat for følgende problemer, skal du tale med lægen
eller apotekspersonalet før vaccination med ProQuad:
 
En allergisk reaktion over for æg eller noget, der indeholdt æg.
 
Tidligere har lidt af allergi eller kramper og anfald, eller det er forekommet i familien.
 
Har oplevet en bivirkning efter vaccination med vacciner indeholdende mæslinger,
fåresyge og/eller røde hunde, som bevirkede, at barnet let fik blå mærker eller blødte
længere end sædvanligt.
 
Er hiv-positiv (hiv = human immundefektvirus) uden symptomer på hiv-infektion. I så fald
kan vaccinationen beskytte mindre effektivt end hos personer uden hiv (se under ProQuad
må ikke anvendes).
Hvis du lider af en blodkoagulationssygdom eller har et lavt niveau trombocytter i dit blod, vil
indsprøjtningen blive givet under huden.
I sjældne tilfælde er det muligt at blive smittet med skoldkopper, herunder svære tilfælde af
skoldkopper, af en person, der er blevet vaccineret med ProQuad. Dette kan forekomme hos personer,
der ikke tidligere er vaccineret mod skoldkopper eller har haft skoldkopper samt hos personer, der
tilhører en af følgende kategorier:
 
Personer med nedsat modstandskraft over for sygdom.
 
Gravide, som ikke har haft skoldkopper eller ikke er vaccineret mod sygdommen.
 
Nyfødte børn af mødre, som ikke har haft skoldkopper eller ikke er vaccineret mod
sygdommen.
Hvis det er muligt, skal personer, som er blevet vaccineret med ProQuad, forsøge at undgå tæt kontakt
med personer, der tilhører en af ovenstående kategorier, i op til 6 uger efter vaccination. Fortæl det til
din læge, hvis du kender nogen, som falder ind under en af disse kategorier, og som du tror, vil
komme i tæt kontakt med personen, der skal vaccineres.
Lige som andre vacciner vil ProQuad muligvis ikke give alle modtagere af vaccinen fuld beskyttelse.
Hvis den, der skal vaccineres, allerede har været udsat for mæslinger, fåresyge, røde hunde eller
skoldkopper, men endnu ikke er syg, vil ProQuad muligvis ikke være i stand til at forhindre
sygdommen i at bryde ud.
Brug af anden medicin sammen med ProQuad
Fortæl altid lægen eller apotekspersonalet, hvis personen, der skal vaccineres, bruger anden medicin
(eller vacciner), for nylig har brugt anden medicin (eller vacciner) eller planlægger at bruge anden
medicin (eller vacciner).
ProQuad kan gives samtidigt med andre børnevacciner som Prevenar og/ eller hepatitis A vaccine,
eller vacciner mod difteri, stivkrampe, kighoste (acellulær), Haemophilus influenzae type b, polio
(inaktiveret) eller hepatitis B. Vaccinerne skal gives på forskellige injektionssteder.
Lægen kan udsætte din vaccination i mindst 3 måneder efter en blod- eller plasmatransfusion eller
indgift af immunglobulin (Ig) eller varicella-zoster-immunglobulin (VZIG). Efter vaccination med
ProQuad bør Ig eller VZIG ikke gives i mindst 1 måned, medmindre lægen siger noget andet. </p>
<p>41
Hvis der skal foretages tuberkulintest, skal den udføres enten før, samtidig med eller mindst 4-6 uger
efter vaccination med ProQuad.
Fortæl lægen, hvis den person, der skal vaccineres, er vaccineret for nylig, eller hvis der er planer om
vaccination i den nærmeste fremtid. Lægen vil så tage stilling til, hvornår ProQuad kan anvendes. 
Brug af salicylater (for eksempel acetylsalicylsyre, som indgår i en række midler til smertelindring og
febersænkning) bør undgås i 6 uger efter vaccination med ProQuad.
Graviditet og amning
ProQuad bør ikke gives til gravide kvinder. Kvinder i den fødedygtige alder skal sikre sig mod
graviditet i 1 måned efter vaccinationen.
Kvinder, der ammer eller har til hensigt at amme, bør fortælle det til deres læge. Lægen vil så tage
stilling til, om ProQuad bør anvendes.
Hvis du er gravid eller ammer, har mistanke om at du er gravid eller planlægger at blive gravid, skal
du spørge din læge eller apotekspersonalet til råds, før du får denne vaccine.
ProQuad indeholder natrium
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. dosis, dvs. det er i det
væsentlige natriumfrit.
ProQuad indeholder kalium
Dette lægemiddel indeholder mindre end 1 mmol (39 mg) kalium pr. dosis, dvs. det er i det væsentlige
kaliumfrit.
ProQuad indeholder sorbitol
Dette lægemiddel indeholder 16 mg sorbitol pr. dosis. Den additive virkning af samtidigt
administrerede produkter indeholdende sorbitol (eller fructose) og indtagelse af sorbitol (eller
fructose) i kosten bør tages i betragtning.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take proquad"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take proquad"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>ProQuad skal gives som indsprøjtning i en muskel eller under huden enten på yderlåret eller på
overarmen.
Normalt foretrækkes indsprøjtninger i yderlåret hos små børn, mens det foretrukne indsprøjtningssted
for ældre patienter er i overarmen.
Hvis den person, der skal vaccineres, lider af en blodkoagulationssygdom eller har et lavt niveau
trombocytter, skal vaccinen gives under huden, fordi der kan opstå blødning efter indsprøjtning i en
muskel.
ProQuad må ikke gives direkte i et blodkar. 
ProQuad gives som indsprøjtning som følger:
 
Spædbørn mellem 9 og 12 måneder:
ProQuad kan indgives fra 9-måneders alderen. For at sikre optimal beskyttelse mod skoldkopper
og mæslinger skal der gives to doser ProQuad med mindst 3 måneders mellemrum.
 
Personer fra 12 måneder og ældre:
For at sikre optimal beskyttelse mod skoldkopper skal der gives to doser ProQuad med mindst
en måneds mellemrum.
Tidspunktet for og antallet af indsprøjtninger fastsættes af din læge i henhold til de officielle
retningslinjer.</p>
<p>42
Vejledning i rekonstitution af vaccinen beregnet for læger og sundhedspersonale er anført sidst i
indlægssedlen
Hvis du glemmer at få ProQuad
Din læge afgør, hvornår den manglende dosis skal gives.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Denne vaccine kan som alle andre vacciner og lægemidler give bivirkninger, men ikke alle får
bivirkninger.
Der kan forekomme allergiske reaktioner (nældefeber). Nogle af disse reaktioner kan være alvorlige
og omfatte åndedrætsbesvær eller synkebesvær. Hvis den vaccinerede person får en allergisk reaktion,
skal du omgående søge læge.
Der er rapporteret andre bivirkninger efter indgivelse af ProQuad, og nogle af disse var alvorlige. Der
var tale om:
 
Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer): krampeanfald med feber.
 
Sjældne (kan forekomme hos op til 1 ud af 1000 personer): usikker gang.
Følgende andre bivirkninger er rapporteret i forbindelse med brug af ProQuad: 
 
Meget almindelige (kan forekomme hos flere end 1 ud af 10 personer): symptomer ved
injektionsstedet inklusive smerte/ømhed, rødmen, feber (38,9°C eller højere).
 
Almindelige (kan forekomme hos op til 1 ud af 10 personer): symptomer ved injektionsstedet
inklusive hævelse eller blå mærker; irritabilitet; udslæt (inklusive mæslingelignende udslæt,
skoldkoppelignende udslæt  og udslæt ved injektionsstedet); øvre luftvejsinfektion,
opkastninger samt diaré.
Andre bivirkninger rapporteret med brug af mindst en af følgende: ProQuad, tidligere formuleringer af
monovalent og af de kombinerede mæslinge-, fåresyge- og røde hundevacciner produceret af Merck &amp;
Co., Inc., eller levende skoldkoppevaccine (Oka/Merck). Disse bivirkninger omfatter:
 
Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer): hoste.
 
Sjældne (kan forekomme hos op til 1 ud af 1.000 personer): hudinfektion; skoldkopper
(varicella).
 
Ikke kendt (hyppigheden kan ikke estimeres ud fra forhåndenværende data): usædvanlig
blødning eller blå mærker under huden; hævelse af testikler; prikken i huden, herpes zoster
(helvedesild); hjernebetændelse (encephalitis); betændelse i de hinder, der omgiver hjernen og
rygmarven, som ikke er forårsaget af en bakteriel infektion (aseptisk meningitis); svære
hudreaktioner; slagtilfælde; kramper uden feber; ledsmerter og/eller hævelse (forbigående eller
kronisk) og lungebetændelse (pneumoni/pneumonitis).
Lægen har en mere udtømmende liste over bivirkninger ved ProQuad og vaccinens enkelte
komponenter (MFR-vaccinen fremstillet af Merck &amp; Co., Inc. og levende skoldkoppevaccine
(Oka/Merck)).
Indberetning af bivirkninger
Hvis den vaccinerede person oplever bivirkninger, bør du tale med din læge eller apotekspersonalet.
Dette gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine
pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale
rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at
fremskaffe mere information om sikkerheden af dette lægemiddel.</p>
<p>43</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store proquad"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store proquad"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar vaccinen utilgængeligt for børn.
Brug ikke denne vaccine efter den udløbsdato, der står på den ydre karton efter EXP. Udløbsdatoen er
den sidste dag i den nævnte måned.
Opbevares og transporteres nedkølet (2° C - 8° C).
Må ikke nedfryses.
Opbevar hætteglasset i den ydre karton for at beskytte det mod lys.
Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>ProQuad indeholder:
Efter rekonstitution indeholder 1 dosis (0,5 ml):</p>
<ul>
<li>Aktive stoffer:
Mæslingevirus1 Enders Edmonston stamme (levende, svækket) ...........≥ 3,00 log10 TCID50<em> Fåresygevirus1 Jeryl LynnTM stamme (levende, svækket (niveau B)) ....≥ 4,30 log10 TCID50</em> Røde hundevirus2 Wistar RA 27/3 stamme (levende, svækket) .............≥ 3,00 log10 TCID50<em> Skoldkoppevirus3 Oka/Merck stamme (levende, svækket) ....................≥ 3,99 log10 PFU</em>* * 50% vævskultur infektiøs dosis</li>
</ul>
<p>** plaquedannende enheder
1) Fremstillet i kyllingefosterceller. 
2) Fremstillet i human diploid lungefibroblast (WI-38).<br />
3) Fremstillet i humane diploide celler (MRC-5). 
- Øvrige indholdsstoffer:
Pulver
Saccharose, hydrolyseret gelatine, urinstof, natriumchlorid, sorbitol (E 420), mononatriumglutamat,
natriumphosphat, natriumbicarbonat, kaliumphosphat, kaliumchlorid, medium 199 med Hanks salte,
MEM, neomycin, phenolrødt, saltsyre, natriumhydroxid.
Solvens
Vand til injektionsvæsker.
Udseende og pakningsstørrelser
Vaccinen fås som pulver til injektionsvæske i et hætteglas med en enkelt dosis, og pulveret skal
opblandes med den solvens, som leveres sammen med hætteglasset med pulver. 
Pulveret er en hvid til lysegul kompakt krystallinsk masse, og solvensen er en klar farveløs væske.
ProQuad fås i pakninger med 1 stk. og pakninger med 10 stk. Ikke alle pakningsstørrelser er
nødvendigvis markedsført.
44
Indehaver af markedsføringstilladelsen og fremstiller
Indehaver af markedsføringstilladelsen: Merck Sharp &amp; Dohme B.V., Waarderweg 39, 2031 BN
Haarlem, Holland
Fremstiller ansvarlig for batchfrigivelse: Merck Sharp and Dohme, B.V., Waarderweg, 39, NL- 2031
BN Haarlem, Holland
Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
MSD Belgium
Tél/Tel: +32(0)27766211
dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme, 
Tel: +370.5.2780.247
msd_lietuva@merck.com
България
Мерк Шарп и Доум България ЕООД 
тел.: + 359 2 819 3737
info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium
Tél/Tel: +32(0)27766211
dpoc_belux@merck.com
Česká republika
Merck Sharp &amp; Dohme s. r. o. 
Tel: +420.233.010.111
dpoc_czechslovak@merck.com
Magyarország
MSD Pharma Hungary Kft 
Tel.: + 36.1.888.5300
hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf: + 45 4482 4000
dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited., Tel:
8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999(+31 23 5153153)
medicalinfo.nl@merck.com
Eesti
Merck Sharp &amp; Dohme OÜ
Tel.: +372 6144 200
msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 00
msdnorge@msd.no
Ελλάδα
MSD Α.Φ.Β.Ε.Ε.
Τηλ: +30 210 98 97 300
dpoc_greece@merck.com
Österreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 044
dpoc_austria@merck.com
España
Merck Sharp &amp; Dohme de España, S.A.
Tel: +34 91 321 06 00
msd_info@merck.com
Polska
MSD Polska Sp. z o.o. 
Tel: +48.22.549.51.00
msdpolska@merck.com
France
MSD France 
Tel:+ 33 (0)1 80 46 40 40
Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465700
inform_pt@merck.com</p>
<p>45
Hrvatska
Merck Sharp &amp; Dohme d.o.o. 
Tel: +385 1 66 11 333
croatia_info@merck.com
România
Merck Sharp &amp; Dohme Romania S.R.L. 
Tel: + 4021 529 29 00
msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfo_ireland@merck.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila d.o.o. 
Tel: +386.1.520.4201
msd.slovenia@merck.com
Ísland
Vistor hf.
Sími: + 354 535 7000
Slovenská republika
Merck Sharp &amp; Dohme, s. r. o.
Tel: +421.2.58282010
dpoc_czechslovak@merck.com
Italia
MSD Italia S.r.l. 
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 650
info@msd.fi
Κύπρος
Merck Sharp &amp; Dohme Cyprus Limited., 
Τηλ: 80 000 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700488
medicinskinfo@merck.com
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: +371.67364.224
msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfoNI@msd.com
Denne indlægsseddel blev senest ændret
Andre informationskilder
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs
hjemmeside http://www.ema.europa.eu.</p>
<hr />
<p>Nedenstående oplysninger er til læger og sundhedspersonale:
Før opblanding med solvensen er vaccinens pulver en hvid til lysegul kompakt krystallinsk masse.
Solvensen er en klar, farveløs væske. Efter fuldstændig rekonstitution er vaccinen en klar lysegul til
lyserød væske.
Til rekonstitution af vaccinen må kun anvendes den medfølgende solvens, idet den er uden
konserveringsmidler eller andre antivirale stoffer, som kunne inaktivere vaccinen. 
Det er vigtigt at anvende en separat steril injektionssprøjte og kanyle til hver enkelt person for at
forebygge transmission af smitsomme stoffer fra en person til en anden.
Der skal anvendes én kanyle til rekonstitution, og en anden separat kanyle skal anvendes til injektion.</p>
<p>46
ProQuad må ikke blandes med andre vacciner i en injektionssprøjte.
Vejledning i rekonstitution
Al solvensen i hætteglasset trækkes op i en injektionssprøjte. Hele sprøjtens indhold injiceres i
hætteglasset med pulver. Omrystes forsigtigt, indtil pulveret er helt opløst. 
Inden administration skal den rekonstituerede vaccine undersøges visuelt for fremmede partikler
og/eller usædvanligt udseende. Hvis noget af dette forekommer, skal vaccinen kasseres.
Det anbefales, at vaccinen gives straks efter rekonstitution for at minimere tab af styrke. Den
rekonstituerede vaccine skal bortskaffes, hvis den ikke anvendes inden for 30 minutter.
Den rekonstituerede vaccine må ikke nedfryses.
Hele hætteglassets indhold af rekonstitueret vaccine trækkes op i en injektionssprøjte, kanylen skiftes
og hele mængden injiceres subkutant eller intramuskulært.
Ikke anvendt lægemiddel samt affald heraf skal bortskaffes i henhold til lokale retningslinjer.
Se også afsnit </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-188ccb87c0d4f4c736200f4cfc1c3e01
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for proquad Package Leaflet for language en"
Description: "ePI document Bundle for proquad Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-188ccb87c0d4f4c736200f4cfc1c3e01"
* entry[0].resource = composition-en-188ccb87c0d4f4c736200f4cfc1c3e01

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp188ccb87c0d4f4c736200f4cfc1c3e01"
* entry[=].resource = mp188ccb87c0d4f4c736200f4cfc1c3e01
                            
                    
Instance: bundlepackageleaflet-da-188ccb87c0d4f4c736200f4cfc1c3e01
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for proquad Package Leaflet for language da"
Description: "ePI document Bundle for proquad Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-188ccb87c0d4f4c736200f4cfc1c3e01"
* entry[0].resource = composition-da-188ccb87c0d4f4c736200f4cfc1c3e01

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp188ccb87c0d4f4c736200f4cfc1c3e01"
* entry[=].resource = mp188ccb87c0d4f4c736200f4cfc1c3e01
                            
                    



Instance: mp188ccb87c0d4f4c736200f4cfc1c3e01
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product ProQuad powder and solvent for suspension for injection"
Description: "ProQuad powder and solvent for suspension for injection"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/05/323/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "ProQuad powder and solvent for suspension for injection"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 188ccb87c0d4f4c736200f4cfc1c3e01ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "proquad"

* status = #current
* mode = #working

* title = "List of all ePIs associated with proquad"

* subject = Reference(mp0ef0c8cd9fea74a67baf8cc292ab700b)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#proquad "proquad"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-188ccb87c0d4f4c736200f4cfc1c3e01) // proquad en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-188ccb87c0d4f4c736200f4cfc1c3e01) // proquad da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-188ccb87c0d4f4c736200f4cfc1c3e01
InstanceOf: List

* insert 188ccb87c0d4f4c736200f4cfc1c3e01ListRuleset
    